Last 12 months
Inside the activity.
0 purchase rows · 24 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 3 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 9 |
| Apr 2026 | 0 | 2 |
| May 2026 | 0 | 3 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 2 |
| Aug 2026 | 0 | 3 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 21, 2017 Filed Feb 23, 2017 23:01 UTC |
Moore Terrence OEVP, CHIEF COMMERCIAL OFFICER
|
SaleCommon Stock | 7,856 | $39.65 | $311,490.40 |
DisclosureSEC source: 0001415889-17-000308 · form4-02232017_030207.xml · nonDerivative · entry 2 Moore Terrence O · CIK 0001454276 · EVP, CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,671 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in September 2015, as amended in June 2016. All sales under the trading plan have been completed. Read SEC document |
| February 21, 2017 Filed Feb 23, 2017 23:01 UTC |
Moore Terrence OEVP, CHIEF COMMERCIAL OFFICER
|
Exercise / conversionCommon Stock | 7,856 | $34.45 | $270,639.20 |
DisclosureSEC source: 0001415889-17-000308 · form4-02232017_030207.xml · nonDerivative · entry 1 Moore Terrence O · CIK 0001454276 · EVP, CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,527 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2017 Filed Feb 17, 2017 00:06 UTC |
Moore Terrence OEVP, CHIEF COMMERCIAL OFFICER
|
Exercise / conversionStock Option (right to buy) · Derivative | 29,644 | $0.00 Strike: $34.35 | $0.00 |
DisclosureSEC source: 0001415889-17-000282 · form4-02162017_040225.xml · derivative · entry 14 Moore Terrence O · CIK 0001454276 · EVP, CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,356 Underlying: Common Stock · 29,644 shares Expires 2025-03-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on March 20, 2016. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments. Read SEC document |
| February 16, 2017 Filed Feb 17, 2017 00:06 UTC |
Moore Terrence OEVP, CHIEF COMMERCIAL OFFICER
|
Exercise / conversionStock Option (right to buy) · Derivative | 19,687 | $0.00 Strike: $27.20 | $0.00 |
DisclosureSEC source: 0001415889-17-000282 · form4-02162017_040225.xml · derivative · entry 13 Moore Terrence O · CIK 0001454276 · EVP, CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,125 Underlying: Common Stock · 19,687 shares Expires 2024-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on March 7, 2015. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments. Read SEC document |
| February 16, 2017 Filed Feb 17, 2017 00:06 UTC |
Moore Terrence OEVP, CHIEF COMMERCIAL OFFICER
|
Exercise / conversionStock Option (right to buy) · Derivative | 17,421 | $0.00 Strike: $19.61 | $0.00 |
DisclosureSEC source: 0001415889-17-000282 · form4-02162017_040225.xml · derivative · entry 12 Moore Terrence O · CIK 0001454276 · EVP, CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,102 Underlying: Common Stock · 17,421 shares Expires 2023-08-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on August 19, 2014. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments. Read SEC document |
| February 16, 2017 Filed Feb 17, 2017 00:06 UTC |
Moore Terrence OEVP, CHIEF COMMERCIAL OFFICER
|
SaleCommon Stock | 66,752 | $39.88 | $2,662,116.49 |
DisclosureSEC source: 0001415889-17-000282 · form4-02162017_040225.xml · nonDerivative · entry 8 Moore Terrence O · CIK 0001454276 · EVP, CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,671 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in September 2015, as amended in June 2016. F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $39.65 to $40.38 per share, inclusive.The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range. Read SEC document |
| February 16, 2017 Filed Feb 17, 2017 00:06 UTC |
Moore Terrence OEVP, CHIEF COMMERCIAL OFFICER
|
Exercise / conversionCommon Stock | 29,644 | $34.45 | $1,021,235.80 |
DisclosureSEC source: 0001415889-17-000282 · form4-02162017_040225.xml · nonDerivative · entry 7 Moore Terrence O · CIK 0001454276 · EVP, CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,423 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2017 Filed Feb 17, 2017 00:06 UTC |
Moore Terrence OEVP, CHIEF COMMERCIAL OFFICER
|
Exercise / conversionCommon Stock | 19,687 | $27.20 | $535,486.40 |
DisclosureSEC source: 0001415889-17-000282 · form4-02162017_040225.xml · nonDerivative · entry 6 Moore Terrence O · CIK 0001454276 · EVP, CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,779 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2017 Filed Feb 17, 2017 00:06 UTC |
Moore Terrence OEVP, CHIEF COMMERCIAL OFFICER
|
Exercise / conversionCommon Stock | 17,421 | $19.61 | $341,625.81 |
DisclosureSEC source: 0001415889-17-000282 · form4-02162017_040225.xml · nonDerivative · entry 5 Moore Terrence O · CIK 0001454276 · EVP, CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,092 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 15, 2017 Filed Feb 17, 2017 00:06 UTC |
Moore Terrence OEVP, CHIEF COMMERCIAL OFFICER
|
Exercise / conversionStock Option (right to buy) · Derivative | 1,700 | $0.00 Strike: $19.61 | $0.00 |
DisclosureSEC source: 0001415889-17-000282 · form4-02162017_040225.xml · derivative · entry 11 Moore Terrence O · CIK 0001454276 · EVP, CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,523 Underlying: Common Stock · 1,700 shares Expires 2023-08-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on August 19, 2014. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments. Read SEC document |
| February 15, 2017 Filed Feb 17, 2017 00:06 UTC |
Moore Terrence OEVP, CHIEF COMMERCIAL OFFICER
|
SaleCommon Stock | 1,700 | $39.65 | $67,405.00 |
DisclosureSEC source: 0001415889-17-000282 · form4-02162017_040225.xml · nonDerivative · entry 4 Moore Terrence O · CIK 0001454276 · EVP, CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,671 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in September 2015, as amended in June 2016. Read SEC document |
| February 15, 2017 Filed Feb 17, 2017 00:06 UTC |
Moore Terrence OEVP, CHIEF COMMERCIAL OFFICER
|
Exercise / conversionCommon Stock | 1,700 | $19.61 | $33,337.00 |
DisclosureSEC source: 0001415889-17-000282 · form4-02162017_040225.xml · nonDerivative · entry 3 Moore Terrence O · CIK 0001454276 · EVP, CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,371 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:06 UTC |
Moore Terrence OEVP, CHIEF COMMERCIAL OFFICER
|
Exercise / conversionStock Option (right to buy) · Derivative | 74,381 | $0.00 Strike: $19.61 | $0.00 |
DisclosureSEC source: 0001415889-17-000282 · form4-02162017_040225.xml · derivative · entry 10 Moore Terrence O · CIK 0001454276 · EVP, CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,223 Underlying: Common Stock · 74,381 shares Expires 2023-08-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on August 19, 2014. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:06 UTC |
Moore Terrence OEVP, CHIEF COMMERCIAL OFFICER
|
Exercise / conversionStock Option (right to buy) · Derivative | 12,747 | $0.00 Strike: $19.61 | $0.00 |
DisclosureSEC source: 0001415889-17-000282 · form4-02162017_040225.xml · derivative · entry 9 Moore Terrence O · CIK 0001454276 · EVP, CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,649 Underlying: Common Stock · 12,747 shares Expires 2023-08-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on August 19, 2014. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:06 UTC |
Moore Terrence OEVP, CHIEF COMMERCIAL OFFICER
|
SaleCommon Stock | 89,088 | $39.69 | $3,535,573.09 |
DisclosureSEC source: 0001415889-17-000282 · form4-02162017_040225.xml · nonDerivative · entry 2 Moore Terrence O · CIK 0001454276 · EVP, CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,671 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in September 2015, as amended in June 2016. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $39.65 to $39.72 per share, inclusive.The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:06 UTC |
Moore Terrence OEVP, CHIEF COMMERCIAL OFFICER
|
Exercise / conversionCommon Stock | 87,128 | $19.61 | $1,708,580.08 |
DisclosureSEC source: 0001415889-17-000282 · form4-02162017_040225.xml · nonDerivative · entry 1 Moore Terrence O · CIK 0001454276 · EVP, CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,759 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 717, 1,243, 461 and 1,210 shares acquired in November 2014, May 2015, November 2015 and May 2016, respectively, by Mr. Moore under the ACADIA Pharmaceuticals Employee Stock Purchase Plan, as amended. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:05 UTC |
Baity GlennEVP AND GC
|
Exercise / conversionStock Option (right to buy) · Derivative | 6,365 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001415889-17-000281 · form4-02162017_040242.xml · derivative · entry 6 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,365 shares Expires 2018-10-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on October 22, 2009. The remaining shares vested and became exercisable thereafter in 36 equal monthly installments. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:05 UTC |
Baity GlennEVP AND GC
|
Exercise / conversionStock Option (right to buy) · Derivative | 3,224 | $0.00 Strike: $8.32 | $0.00 |
DisclosureSEC source: 0001415889-17-000281 · form4-02162017_040242.xml · derivative · entry 5 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,224 shares Expires 2018-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on March 7, 2009. The remaining shares vested and became exercisable thereafter in 36 equal monthly installments. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:05 UTC |
Baity GlennEVP AND GC
|
Exercise / conversionStock Option (right to buy) · Derivative | 16,776 | $0.00 Strike: $8.32 | $0.00 |
DisclosureSEC source: 0001415889-17-000281 · form4-02162017_040242.xml · derivative · entry 4 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,776 shares Expires 2018-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on March 7, 2009. The remaining shares vested and became exercisable thereafter in 36 equal monthly installments. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:05 UTC |
Baity GlennEVP AND GC
|
SaleCommon Stock | 26,365 | $39.66 | $1,045,517.26 |
DisclosureSEC source: 0001415889-17-000281 · form4-02162017_040242.xml · nonDerivative · entry 3 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,063 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in September 2015, as amended in May 2016. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $39.65 to $39.71 per share, inclusive.The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:05 UTC |
Baity GlennEVP AND GC
|
Exercise / conversionCommon Stock | 6,365 | $1.64 | $10,438.60 |
DisclosureSEC source: 0001415889-17-000281 · form4-02162017_040242.xml · nonDerivative · entry 2 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,428 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:05 UTC |
Baity GlennEVP AND GC
|
Exercise / conversionCommon Stock | 20,000 | $8.32 | $166,400.00 |
DisclosureSEC source: 0001415889-17-000281 · form4-02162017_040242.xml · nonDerivative · entry 1 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 23:50 UTC |
Baity GlennEVP AND GC
|
Exercise / conversionStock Option (right to buy) · Derivative | 21,078 | $0.00 Strike: $1.55 | $0.00 |
DisclosureSEC source: 0001415889-17-000182 · form4-02032017_030250.xml · derivative · entry 3 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,078 shares Expires 2020-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on March 12, 2011. The remaining shares vested and became exercisable thereafter in 36 equal monthly installments. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 23:50 UTC |
Baity GlennEVP AND GC
|
SaleCommon Stock | 31,078 | $35.15 | $1,092,382.38 |
DisclosureSEC source: 0001415889-17-000182 · form4-02032017_030250.xml · nonDerivative · entry 2 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,063 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in August 2016. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.10 to $35.315 per share, inclusive.The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 23:50 UTC |
Baity GlennEVP AND GC
|
Exercise / conversionCommon Stock | 21,078 | $1.55 | $32,670.90 |
DisclosureSEC source: 0001415889-17-000182 · form4-02032017_030250.xml · nonDerivative · entry 1 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,141 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 28, 2016 Filed Dec 29, 2016 22:09 UTC |
Baity GlennEVP AND GC
|
Exercise / conversionStock Option (right to buy) · Derivative | 5,500 | $0.00 Strike: $1.62 | $0.00 |
DisclosureSEC source: 0001415889-16-007636 · form4-12292016_021237.xml · derivative · entry 5 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,093 Underlying: Common Stock · 5,500 shares Expires 2021-03-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on March 25, 2012. The remaining shares vested and became exercisable thereafter in 36 equal monthly installments. Read SEC document |
| December 28, 2016 Filed Dec 29, 2016 22:09 UTC |
Baity GlennEVP AND GC
|
Exercise / conversionCommon Stock | 5,500 | $1.62 | $8,910.00 |
DisclosureSEC source: 0001415889-16-007636 · form4-12292016_021237.xml · nonDerivative · entry 3 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 27, 2016 Filed Dec 29, 2016 22:09 UTC |
Baity GlennEVP AND GC
|
Exercise / conversionStock Option (right to buy) · Derivative | 9,800 | $0.00 Strike: $1.55 | $0.00 |
DisclosureSEC source: 0001415889-16-007636 · form4-12292016_021237.xml · derivative · entry 4 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,078 Underlying: Common Stock · 9,800 shares Expires 2020-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on March 12, 2011. The remaining shares vested and became exercisable thereafter in 36 equal monthly installments. Read SEC document |
| December 27, 2016 Filed Dec 29, 2016 22:09 UTC |
Baity GlennEVP AND GC
|
SaleCommon Stock | 9,800 | $30.46 | $298,473.70 |
DisclosureSEC source: 0001415889-16-007636 · form4-12292016_021237.xml · nonDerivative · entry 2 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,563 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in August 2016. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $30.28 to $30.60 per share, inclusive.The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range. Read SEC document |
| December 27, 2016 Filed Dec 29, 2016 22:09 UTC |
Baity GlennEVP AND GC
|
Exercise / conversionCommon Stock | 9,800 | $1.55 | $15,190.00 |
DisclosureSEC source: 0001415889-16-007636 · form4-12292016_021237.xml · nonDerivative · entry 1 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,363 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 20, 2016 Filed Dec 22, 2016 00:03 UTC |
Baity GlennEVP AND GC
|
Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $1.55 | $0.00 |
DisclosureSEC source: 0001415889-16-007629 · form4-12212016_041225.xml · derivative · entry 5 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,878 Underlying: Common Stock · 10,000 shares Expires 2020-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on March 12, 2011. The remaining shares vested and became exercisable thereafter in 36 equal monthly installments. Read SEC document |
| December 20, 2016 Filed Dec 22, 2016 00:03 UTC |
Baity GlennEVP AND GC
|
SaleCommon Stock | 10,000 | $30.00 | $300,001.00 |
DisclosureSEC source: 0001415889-16-007629 · form4-12212016_041225.xml · nonDerivative · entry 3 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,563 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in August 2016. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.01 per share, inclusive.The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range. Read SEC document |
| December 20, 2016 Filed Dec 22, 2016 00:03 UTC |
Baity GlennEVP AND GC
|
Exercise / conversionCommon Stock | 10,000 | $1.55 | $15,500.00 |
DisclosureSEC source: 0001415889-16-007629 · form4-12212016_041225.xml · nonDerivative · entry 2 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,563 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 19, 2016 Filed Dec 22, 2016 00:03 UTC |
Baity GlennEVP AND GC
|
Exercise / conversionStock Option (right to buy) · Derivative | 8,635 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001415889-16-007629 · form4-12212016_041225.xml · derivative · entry 4 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,635 shares Expires 2018-10-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on October 22, 2009. The remaining shares vested and beaome exercisable thereafter in 36 equal monthly installments. Read SEC document |
| December 19, 2016 Filed Dec 22, 2016 00:03 UTC |
Baity GlennEVP AND GC
|
Exercise / conversionCommon Stock | 8,635 | $1.64 | $14,161.40 |
DisclosureSEC source: 0001415889-16-007629 · form4-12212016_041225.xml · nonDerivative · entry 1 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,563 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 7 shares acquired on November 15, 2016 by Mr. Baity under the ACADIA Pharmaceuticals Employee Stock Purchase Plan. Read SEC document |
| November 10, 2016 Filed Nov 15, 2016 00:00 UTC |
Baity GlennEVP AND GC
|
Exercise / conversionStock Option (right to buy) · Derivative | 10,200 | $0.00 Strike: $1.55 | $0.00 |
DisclosureSEC source: 0001415889-16-007417 · form4-11142016_041144.xml · derivative · entry 3 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,878 Underlying: Common Stock · 10,200 shares Expires 2020-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on March 12, 2011. The remaining shares vested and became exercisable thereafter in 36 equal monthly installments. Read SEC document |
| November 10, 2016 Filed Nov 15, 2016 00:00 UTC |
Baity GlennEVP AND GC
|
SaleCommon Stock | 10,200 | $30.07 | $306,687.48 |
DisclosureSEC source: 0001415889-16-007417 · form4-11142016_041144.xml · nonDerivative · entry 2 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,921 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in August 2016. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.17 per share, inclusive.The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range. Read SEC document |
| November 10, 2016 Filed Nov 15, 2016 00:00 UTC |
Baity GlennEVP AND GC
|
Exercise / conversionCommon Stock | 10,200 | $1.55 | $15,810.00 |
DisclosureSEC source: 0001415889-16-007417 · form4-11142016_041144.xml · nonDerivative · entry 1 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,121 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.